Paper Details

  1. Home
  2. Paper Details

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Author: FeigerAlan D, RickelsKarl, RobinsonDonald S, RynnMoira A, ZimbroffDan L

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

The study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) for treating major depressive disorder (MDD). The results showed that STS was significantly more effective than placebo in improving depression symptoms, with a modest treatment effect primarily due to insomnia side effects. The study concluded that STS has an improved margin of safety compared with oral monoamine oxidase inhibitors and represents a useful addition to the existing array of antidepressants.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD). METHOD: Patients meeting DSM-IV criteria for MDD (N = 265) were randomly...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4088/jcp.v67n0905

データ提供：米国国立医学図書館（NLM）

Treating Depression: A Transdermal Approach with Selegiline

Major depressive disorder (MDD) is a debilitating condition that affects millions worldwide. This study investigates the efficacy and safety of a transdermal selegiline system (STS) for treating MDD.

The researchers conducted a double-blind, placebo-controlled, flexible-dose titration trial involving patients meeting DSM-IV criteria for MDD. The findings demonstrate that STS, when administered in a dose range of 6 mg/24 hours to 12 mg/24 hours, significantly improved symptoms of depression compared to placebo. The study also highlights the safety and tolerability of STS, indicating it as a potential alternative to oral monoamine oxidase inhibitors.

A New Oasis in the Desert of Depression

Imagine a vast desert landscape, representing the challenging journey of living with MDD. This research, like a refreshing oasis in the midst of this arid terrain, offers hope for a more effective and safe treatment option. The study's findings suggest that STS could provide relief from the debilitating symptoms of depression, potentially leading to a more fulfilling and meaningful life.

Navigating the Sands of Depression: A Personalized Approach

Just as a traveler chooses the best route to navigate a desert, patients with MDD need a personalized approach to treatment. This study, like a compass guiding travelers through a vast desert, helps us understand the potential benefits of STS, enabling us to select the most effective and safe treatment based on individual needs and circumstances.

Dr. Camel's Conclusion

This study, like a caravan carrying precious cargo through a desert, delivers a promising new approach to treating depression. STS, with its transdermal delivery system and potential for greater efficacy and safety, could transform the landscape of depression care. This breakthrough could lead to a more hopeful and empowering future for individuals struggling with this debilitating condition.
Date :
  1. Date Completed 2006-11-06
  2. Date Revised 2019-09-02
Further Info :

Pubmed ID

17017821

DOI: Digital Object Identifier

10.4088/jcp.v67n0905

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.